Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version v2.16.2 to v2.16.3.SummaryDifference0.0%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check42 days agoChange DetectedThe page has removed a citation for a clinical trial regarding Cabozantinib versus Sunitinib for metastatic renal cell carcinoma, which included important erratum details.SummaryDifference0.4%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.